A Study of Setmelanotide in Patients With Prader-Willi Syndrome

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions

Prader-Willi SyndromeObesityHyperphagia

Interventions

DRUG

Setmelanotide

Setmelanotide (daily subcutaneous injection)

Trial Locations (1)

RECRUITING

University of Florida, Gainesville

All Listed Sponsors

lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY